Y X Pan

Publications (3)13.15 Total impact

• Source

  Available from: sapmed.ac.jp

  Article: Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients.

  Y J La, C L Wan, H Zhu, Y F Yang, Y S Chen, Y X Pan, G Y Feng, L He
  [show abstract] [hide abstract]
  ABSTRACT: This study aims to identify the effects of antipsychotics on plasma proteins, and on the proteins associated with schizophrenia. We applied proteomics technology to screen protein aberrations in Sprague-Dawley rats treated with antipsychotics and schizophrenic patients undergoing medication. ApoA-I was found significantly increased in the chlorpromazine-treated rats and decreased in the patients with treatment-resistant schizophrenia, which suggest that decreased levels of apoA-I might be associated with the pathology of schizophrenia and that chlorpromazine increases apoA-I levels as part of its therapeutic action.
  Acta Neurovegetativa 02/2007; 114(5):657-63. · 2.73 Impact Factor
• Article: Interleukin-10 -1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study.

  G He, J Zhang, X W Li, W Y Chen, Y X Pan, F P Yang, N F Gu, G Y Feng, S L Yang, J Y He, B X Liu, Y W Peng, J Liu, L He
  [show abstract] [hide abstract]
  ABSTRACT: The interleukin-10 (IL-10) gene has been identified as a susceptibility gene for schizophrenia in Caucasians. A previous case-control study conducted by our group revealed a weak association between polymorphism, -592C/A, of the IL-10 gene promoter and schizophrenia. Our present study was aimed at confirming the association of the IL-10 promoter with schizophrenia using 197 Han Chinese sib-pair families. A family-based association test (FBAT) and haplotype analysis was undertaken using the FBAT v1.5.5. The global TDT was significant for a different polymorphism, -1082G/A (chi2=13.16, P=0.000285) and that the allele -1082G was preferentially transmitted to schizophrenia-affected children. Furthermore, haplotype TDT analysis showed that haplotype "GCC" was significantly associated with the disease (chi2=8.1, P=0.00443). Our results also indicate that the IL-10 gene may play a significant role in the etiology of schizophrenia among Han Chinese.
  Neuroscience Letters 03/2006; 394(1):1-4. · 2.11 Impact Factor
• Article: Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese.

  L Bian, J D Yang, T W Guo, Y Sun, S W Duan, W Y Chen, Y X Pan, G Y Feng, L He
  [show abstract] [hide abstract]
  ABSTRACT: The gene for insulin-degrading enzyme (IDE) represents a strong positional and biologic candidate for late-onset Alzheimer disease (LOAD) susceptibility. IDE is located on chromosome 10q23.3 close to a region of linkage for LOAD. In addition, many studies have identified a possible role of IDE in the degradation of amyloid beta-protein and the intracellular amyloid precursor protein (APP) domain released by gamma-secretase processing. To examine the association of IDE with AD in the Han Chinese. Four IDE polymorphisms (three in 5'-untranslated region and one in intron 21) were analyzed, using a population of 210 patients with LOAD and 200 control subjects well matched for age, sex, and ethnic background. Among the four polymorphisms studied, only the C allele of single-nucleotide polymorphism (SNP) IDE2 showed association with AD (p = 0.005). Stratification of the data by APOE epsilon4 status indicated that the association between IDE2 and AD was confined to APOE epsilon4 carriers only. No association was found between all variants studied and AD within APOE epsilon4-negative subjects. The global haplotype frequencies showed significant differences between AD patients and control subjects. Furthermore, overrepresentation of GCTG haplotype in the AD group was found. It may be a risk haplotype for AD. These results suggest a possible synergic interaction between IDE and APOE epsilon4 in the risk to develop late-onset sporadic AD. IDE might modify the effect of the APOE epsilon4 risk factor in the Han Chinese population.
  Neurology 08/2004; 63(2):241-5. · 8.31 Impact Factor